. La-streptavidine-marquée-par-la-phosphatase-alcaline, SAV-PA) et la solution de BCIP/NBT prête à l'emploi proviennent de Sigma-Aldrich

L. Anticorps-de-capture-anti-il6-humaine, Les anticorps sont développés chez la souris, 13A5) et anti-IL10 humaine (clone JES-9D7), les anticorps biotinylés anti-IL6 humaine (MQ2-39C3) et anti-IL10 humaine (JES3-12G8), ainsi que les protéines recombinantes IL6 et IL10 humaines ont été fournis par eBioscience

Z. Hu, H. Huang, C. Wu, M. Jung, A. Dritschilo et al., Omics-Based Molecular Target and Biomarker Identification, Methods Mol Biol Clifton NJ, vol.719, pp.547-71, 2011.
DOI : 10.1007/978-1-61779-027-0_26

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742302

S. Cho and J. , Personalized Medicine in Breast Cancer: A Systematic Review, Journal of Breast Cancer, vol.15, issue.3, pp.265-72, 2012.
DOI : 10.4048/jbc.2012.15.3.265

H. Francim, J. De-lyon-ferlay, H. Shin, F. Bray, D. Forman et al., Les données -Institut National Du cancer -Incidence et mortalité estimées des cancers en France métropolitaine en 2012 [Internet]. [consulté le 5 sept Disponbile en ligne: http://lesdonnees.e-cancer.fr/les-indicateurs/29-incidence-mortalite/38-ensemble- des-cancers/28-epidemiologie-des-cancers-en-france-metropolitaine-incidence/45- incidence-mortalite-estimees-cancers-france-metropolitaine-tous-sexes.html 7, Cancer Incidence and Mortality Worldwide: IARC CancerBase No, D. Global cancer statistics, pp.69-90, 2010.

M. Ploeg, K. Aben, and L. Kiemeney, The present and future burden of urinary bladder cancer in the world, World Journal of Urology, vol.102, issue.2, pp.289-93, 2009.
DOI : 10.1007/s00345-009-0383-3

A. Felix, A. Soliman, H. Khaled, M. Zaghloul, M. Banerjee et al., The changing patterns of bladder cancer in Egypt over the past 26??years, Cancer Causes & Control, vol.28, issue.4, pp.421-430, 2008.
DOI : 10.1007/s10552-007-9104-7

J. Denef, Le système urinaire [Internet]. [consulté le 9 sept, Disponible en ligne, 2013.

N. Nccn, Clinical Practice Guidelines Bladder Cancer Disponible en ligne, 2013.

C. Pfister, M. Roupret, H. Wallerand, J. Davin, H. Quintens et al., Recommandations en Onco-Urologie 2010 : Tumeurs uroth??liales, Progr??s en Urologie, vol.20, pp.255-274, 2010.
DOI : 10.1016/S1166-7087(10)70043-9

R. Sylvester, A. Van-der-meijden, W. Oosterlinck, J. Witjes, C. Bouffioux et al., Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials, European Urology, vol.49, issue.3, pp.466-465, 2006.
DOI : 10.1016/j.eururo.2005.12.031

E. Eortc, Risk Tables for Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer [Internet], 2006.

S. Sharma, P. Ksheersagar, and P. Sharma, Diagnosis and treatment of bladder cancer, Am Fam Physician, vol.80, issue.7, pp.717-740, 2009.

S. Shariat, J. Karam, Y. Lotan, and P. Karakiewizc, Critical Evaluation of Urinary Markers for Bladder Cancer Detection and Monitoring, Rev Urol, vol.10, issue.2, pp.120-155, 2008.

L. Budman, W. Kassouf, and J. Steinberg, Biomarkers for detection and surveillance of bladder cancer, Canadian Urological Association Journal, vol.2, issue.3, pp.212-233, 2008.
DOI : 10.5489/cuaj.600

D. Vordos and G. Ploussard, Cystoscopie en fluorescence pour les tumeurs superficielles de vessie : apport de l???hexaminol??vulinate (Hexvix??) et du diagnostic photodynamique, Progr??s en Urologie - FMC, vol.19, issue.1, pp.9-14, 2009.
DOI : 10.1016/S1761-676X(09)70028-8

A. Van-tilborg, C. Bangma, and E. Zwarthoff, Bladder cancer biomarkers and their role in surveillance and screening, International Journal of Urology, vol.26, issue.1, pp.23-30, 2009.
DOI : 10.1111/j.1442-2042.2008.02174.x

M. Van-der-aa, E. Steyerberg, E. Sen, E. Zwarthoff, W. Kirkels et al., Patients??? perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison, BJU International, vol.66, issue.9, pp.1106-1116, 2008.
DOI : 10.1016/j.urology.2004.09.050

M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle et al., EAU Guidelines on Non???Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update, European Urology, vol.59, issue.6, pp.997-1008, 2011.
DOI : 10.1016/j.eururo.2011.03.017

. Infocancer and . La-chimiothérapie-générale, 2009 [consulté le 11 sept. 2013] Available from

K. Sievert, B. Amend, U. Nagele, D. Schilling, J. Bedke et al., Economic aspects of bladder cancer: what are the benefits and costs?, World Journal of Urology, vol.42, issue.Suppl 1, pp.295-300, 2009.
DOI : 10.1007/s00345-009-0395-z

R. Kinders, T. Jones, R. Root, C. Bruce, H. Murchison et al., Complement factor H or a related protein is a marker for transitional cell cancer of the bladder, Clin Cancer Res, vol.4, issue.10, pp.2511-2531, 1998.

J. Campos-fernandes, F. Descotes, J. Andre, P. Perrin, M. Devonec et al., Int??r??t des marqueurs urinaires dans le diagnostic et le suivi des tumeurs uroth??liales de vessie, Progr??s en Urologie, vol.17, issue.1, pp.23-34, 2007.
DOI : 10.1016/S1166-7087(07)92221-6

Z. Cheng, M. Corey, M. Pärepalo, S. Majno, J. Hellwage et al., Complement Factor H as a Marker for Detection of Bladder Cancer, Clinical Chemistry, vol.51, issue.5, pp.856-63, 2005.
DOI : 10.1373/clinchem.2004.042192

O. Vrooman and J. Witjes, Urinary Markers in Bladder Cancer, European Urology, vol.53, issue.5, pp.909-925, 2008.
DOI : 10.1016/j.eururo.2007.12.006

B. Konety, T. Nguyen, R. Dhir, R. Day, M. Becich et al., Detection of Bladder Cancer Using a Novel Nuclear Matrix Protein, BLCA-4, Clin Cancer Res, vol.6, issue.7, pp.2618-2643, 2000.

T. Van-le, R. Miller, T. Barder, M. Babjuk, D. Potter et al., RETRACTED: Highly specific urine-based marker of bladder cancer, Urology, vol.66, issue.6, pp.1256-60, 2005.
DOI : 10.1016/j.urology.2005.07.010

D. Seripa, P. Parrella, M. Gallucci, C. Gravina, S. Papa et al., Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine, International Journal of Cancer, vol.89, issue.6, pp.364-373, 2001.
DOI : 10.1002/1097-0215(20011120)95:6<364::AID-IJC1064>3.0.CO;2-V

J. Parker and P. Spiess, Current and Emerging Bladder Cancer Urinary Biomarkers, The Scientific World JOURNAL, vol.11, pp.1103-1115, 2011.
DOI : 10.1100/tsw.2011.104

URL : http://doi.org/10.1100/tsw.2011.104

M. Hou, D. Xu, M. Björkholm, and A. Gruber, Real-Time Quantitative Telomeric Repeat Amplification Protocol Assay for the Detection of Telomerase Activity, Clin Chem, vol.47, issue.3, pp.519-543, 2001.

A. Glas, D. Roos, M. Deutekom, A. Zwinderman, P. Bossuyt et al., Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic Review, The Journal of Urology, vol.169, issue.6, pp.1975-82, 2003.
DOI : 10.1097/01.ju.0000067461.30468.6d

J. Fernandez-gomez, J. Rodríguez-martínez, S. Barmadah, G. Rodríguez, J. Allende et al., Urinary CYFRA 21.1 Is Not a Useful Marker for the Detection of Recurrences in the Follow-Up of Superficial Bladder Cancer, European Urology, vol.51, issue.5, pp.1267-74, 2007.
DOI : 10.1016/j.eururo.2006.12.019

V. Lokeshwar, C. Obek, H. Pham, D. Wei, M. Young et al., URINARY HYALURONIC ACID AND HYALURONIDASE:, The Journal of Urology, vol.163, issue.1, pp.348-56, 2000.
DOI : 10.1097/00005392-200001000-00093

V. Lokeshwar, W. Cerwinka, and B. Lokeshwar, HYAL1 Hyaluronidase: A Molecular Determinant of Bladder Tumor Growth and Invasion, Cancer Research, vol.65, issue.6, p.2243, 2005.
DOI : 10.1158/0008-5472.CAN-04-2805

S. Shariat, R. Ashfaq, P. Karakiewicz, O. Saeedi, A. Sagalowsky et al., Survivin expression is associated with bladder cancer presence, stage, progression, and mortality, Cancer, vol.63, issue.33, pp.1106-1119, 2007.
DOI : 10.1002/cncr.22521

O. Moussa, H. Abol-enein, N. Bissada, T. Keane, M. Ghoneim et al., Evaluation of Survivin Reverse Transcriptase-Polymerase Chain Reaction for Noninvasive Detection of Bladder Cancer, The Journal of Urology, vol.175, issue.6, pp.2312-2318, 2006.
DOI : 10.1016/S0022-5347(06)00254-0

S. Shariat, R. Casella, S. Khoddami, G. Hernandez, T. Sulser et al., Urine Detection of Survivin is a Sensitive Marker for the Noninvasive Diagnosis of Bladder Cancer, The Journal of Urology, vol.171, issue.2, pp.626-656, 2004.
DOI : 10.1097/01.ju.0000107826.78479.90

E. Diamandis, How Are We Going to Discover New Cancer Biomarkers? A Proteomic Approach for Bladder Cancer, Clinical Chemistry, vol.50, issue.5, pp.793-798, 2004.
DOI : 10.1373/clinchem.2004.032177

M. Hamburg and F. Collins, The Path to Personalized Medicine, New England Journal of Medicine, vol.363, issue.4, 2010.
DOI : 10.1056/NEJMp1006304

C. Compton, Getting to personalized cancer medicine, Cancer, vol.110, issue.8, pp.1641-1644, 2007.
DOI : 10.1002/cncr.22966

M. Diamandis, N. White, and G. Yousef, Personalized Medicine: Marking a New Epoch in Cancer Patient Management, Molecular Cancer Research, vol.8, issue.9, pp.1175-87, 2010.
DOI : 10.1158/1541-7786.MCR-10-0264

N. Ramachandran, S. Srivastava, and J. Labaer, Applications of protein microarrays for biomarker discovery, PROTEOMICS - CLINICAL APPLICATIONS, vol.1, issue.10-11, pp.10-111444, 2008.
DOI : 10.1002/prca.200800032

M. Ahram and E. Petricoin, Proteomics Discovery of Disease Biomarkers. Biomark Insights, pp.325-358, 2008.

L. Liotta and E. Petricoin, Putting the "Bio" back into Biomarkers: Orienting Proteomic Discovery toward Biology and away from the Measurement Platform, Clinical Chemistry, vol.54, issue.1, pp.3-5, 2008.
DOI : 10.1373/clinchem.2007.097659

G. Reddy and E. Dalmasso, Array Technology: Protein-Based Predictive Medicine and Drug Discovery Applications, Journal of Biomedicine and Biotechnology, vol.2003, issue.4, 2003.
DOI : 10.1155/S1110724303210020

URL : http://doi.org/10.1155/s1110724303210020

A. Vlahou, P. Schellhammer, S. Mendrinos, K. Patel, F. Kondylis et al., Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine, The American Journal of Pathology, vol.158, issue.4, pp.1491-502, 2001.
DOI : 10.1016/S0002-9440(10)64100-4

X. Yu, N. Schneiderhan-marra, and T. Joos, Protein Microarrays for Personalized Medicine, Clinical Chemistry, vol.56, issue.3, pp.376-87, 2010.
DOI : 10.1373/clinchem.2009.137158

T. Ideker, T. Galitski, and L. Hood, : Systems Biology, Annual Review of Genomics and Human Genetics, vol.2, issue.1, pp.343-72, 2001.
DOI : 10.1146/annurev.genom.2.1.343

M. Regenmortel, Reductionism and complexity in molecular biology, EMBO reports, vol.23, issue.11, pp.1016-1036, 2004.
DOI : 10.1046/j.1432-1327.2001.02167.x

V. Kulasingam and E. Diamandis, Strategies for discovering novel cancer biomarkers through utilization of emerging technologies, Nature Clinical Practice Oncology, vol.18, issue.10, 2008.
DOI : 10.1038/ncponc1187

D. Brenner and D. Normolle, Biomarkers for Cancer Risk, Early Detection, and Prognosis: The Validation Conundrum, Cancer Epidemiology Biomarkers & Prevention, vol.16, issue.10, 2007.
DOI : 10.1158/1055-9965.EPI-07-2619

D. Hayes, R. Bast, C. Desch, H. Fritsche, N. Kemeny et al., Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers, JNCI Journal of the National Cancer Institute, vol.88, issue.20, pp.1456-66, 1996.
DOI : 10.1093/jnci/88.20.1456

E. Diamandis, Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, Amer. Assoc. for Clinical Chemistry, 2002.

D. Sargent, B. Conley, A. C. Collette, and L. , Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials, Journal of Clinical Oncology, vol.23, issue.9, pp.2020-2027, 2005.
DOI : 10.1200/JCO.2005.01.112

B. Freidlin, L. Mcshane, and E. Korn, Randomized Clinical Trials With Biomarkers: Design Issues, JNCI Journal of the National Cancer Institute, vol.102, issue.3, pp.152-60, 2010.
DOI : 10.1093/jnci/djp477

P. Febbo, M. Ladanyi, K. Aldape, D. Marzo, A. Hammond et al., NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology, J Natl Compr Cancer Netw JNCCN, vol.9, pp.1-32, 2011.

R. Simon, S. Paik, and D. Hayes, Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers, JNCI Journal of the National Cancer Institute, vol.101, issue.21, pp.1446-52, 2009.
DOI : 10.1093/jnci/djp335

R. Amado, M. Wolf, M. Peeters, E. Van-cutsem, S. Siena et al., Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1660, 2008.
DOI : 10.1200/JCO.2007.14.7116

C. Karapetis, S. Khambata-ford, D. Jonker, O. Callaghan, C. Tu et al., Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer, New England Journal of Medicine, vol.359, issue.17, pp.1757-65, 2008.
DOI : 10.1056/NEJMoa0804385

M. Hartmann, J. Roeraade, D. Stoll, M. Templin, and T. Joos, Protein microarrays for diagnostic assays, Analytical and Bioanalytical Chemistry, vol.20, issue.5, pp.1407-1423, 2009.
DOI : 10.1007/s00216-008-2379-z

A. Ellington, I. Kullo, K. Bailey, and G. Klee, Antibody-Based Protein Multiplex Platforms: Technical and Operational Challenges, Clinical Chemistry, vol.56, issue.2, pp.186-93, 2010.
DOI : 10.1373/clinchem.2009.127514

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901849

L. Liotta, V. Espina, A. Mehta, V. Calvert, K. Rosenblatt et al., Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell, pp.317-342, 2003.

H. Zhu and M. Snyder, Protein chip technology, Current Opinion in Chemical Biology, vol.7, issue.1, pp.55-63, 2003.
DOI : 10.1016/S1367-5931(02)00005-4

G. Mortuaire, P. Marchetti, P. Formstecher, and P. Danzé, Nouvelle approche globale en protéomique : les biopuces à protéines

B. Kersten, E. Wanker, J. Hoheisel, and P. Angenendt, Multiplex approaches in protein microarray technology, Expert Review of Proteomics, vol.2, issue.4, pp.499-510, 2005.
DOI : 10.1586/14789450.2.4.499

B. Schweitzer, P. Predki, and M. Snyder, Microarrays to characterize protein interactions on a whole-proteome scale, PROTEOMICS, vol.3, issue.11, pp.2190-2199, 2003.
DOI : 10.1002/pmic.200300610

G. Michaud, M. Salcius, F. Zhou, R. Bangham, J. Bonin et al., Analyzing antibody specificity with whole proteome microarrays, Nature Biotechnology, vol.21, issue.12, 2003.
DOI : 10.1038/nbt910

V. Espina, A. Mehta, M. Winters, V. Calvert, J. Wulfkuhle et al., Protein microarrays: Molecular profiling technologies for clinical specimens, PROTEOMICS, vol.3, issue.11, pp.2091-100, 2003.
DOI : 10.1002/pmic.200300592

B. Haab, Antibody Arrays in Cancer Research, Molecular & Cellular Proteomics, vol.4, issue.4, pp.377-83, 2005.
DOI : 10.1074/mcp.M500010-MCP200

G. Macbeath, Protein microarrays and proteomics, Nature Genetics, vol.32, issue.Supp, pp.526-558, 2002.
DOI : 10.1038/ng1037

K. Sheehan, V. Calvert, E. Kay, Y. Lu, D. Fishman et al., Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma, Molecular & Cellular Proteomics, vol.4, issue.4, pp.346-55, 2005.
DOI : 10.1074/mcp.T500003-MCP200

D. Shenkenberg, System can detect 9600 proteins or DNA molecules simultaneously, 2008.

Y. Bioprocess and D. Co, AimPlex Multiplex Immunoassay for Flow -How It Works

J. Glökler and P. Angenendt, Protein and antibody microarray technology, Journal of Chromatography B, vol.797, issue.1-2, pp.229-269, 2003.
DOI : 10.1016/j.jchromb.2003.08.034

B. Haab, Methods and applications of antibody microarrays in cancer research, PROTEOMICS, vol.3, issue.11, pp.2116-2138, 2003.
DOI : 10.1002/pmic.200300595

P. Angenendt, Progress in protein and antibody microarray technology. Drug Discov Today, Apr, vol.110, issue.7, pp.503-514, 2005.

C. Massart, Immunoanalyse: De la théorie aux critères de choix en biologie clinique, EDP Sciences, 2012.

S. Kingsmore, Multiplexed protein measurement: technologies and applications of protein and antibody arrays, Nature Reviews Drug Discovery, vol.4, issue.4, pp.310-330, 2006.
DOI : 10.1007/s11095-005-2495-9

B. Schweitzer, S. Roberts, B. Grimwade, W. Shao, M. Wang et al., Multiplexed protein profiling on microarrays by rolling-circle amplification, Nature Biotechnology, vol.20, issue.4, 2002.
DOI : 10.1038/nbt0402-359

B. Schweitzer, S. Wiltshire, J. Lambert, O. Malley, S. Kukanskis et al., Immunoassays with rolling circle DNA amplification: A versatile platform for ultrasensitive antigen detection, Proceedings of the National Academy of Sciences, vol.97, issue.18, pp.10113-10122, 2000.
DOI : 10.1073/pnas.170237197

H. Koga, M. Kyo, K. Usui-aoki, and K. Inamori, A chip-based miniaturized format for protein-expression profiling: The exploitation of comprehensively produced antibodies, ELECTROPHORESIS, vol.85, issue.18, pp.3676-83, 2006.
DOI : 10.1002/elps.200500821

X. Yu, D. Xu, and Q. Cheng, Label-free detection methods for protein microarrays, PROTEOMICS, vol.21, issue.20, pp.5493-503, 2006.
DOI : 10.1002/pmic.200600216

K. Usui-aoki, K. Shimada, M. Nagano, M. Kawai, and H. Koga, A novel approach to protein expression profiling using antibody microarrays combined with surface plasmon resonance technology, PROTEOMICS, vol.1, issue.9, pp.2396-401, 2005.
DOI : 10.1002/pmic.200401171

H. Zhu, M. Bilgin, R. Bangham, D. Hall, A. Casamayor et al., Global Analysis of Protein Activities Using Proteome Chips, Science, vol.293, issue.5537, pp.2101-2106, 2001.
DOI : 10.1126/science.1062191

B. Houseman, J. Huh, S. Kron, and M. Mrksich, Peptide chips for the quantitative evaluation of protein kinase activity, Nature Biotechnology, vol.20, issue.3, pp.270-274, 2002.
DOI : 10.1038/nbt0302-270

J. Wulfkuhle, R. Speer, M. Pierobon, J. Laird, V. Espina et al., Multiplexed Cell Signaling Analysis of Human Breast Cancer Applications for Personalized Therapy, Journal of Proteome Research, vol.7, issue.4, pp.1508-1525, 2008.
DOI : 10.1021/pr7008127

R. Hiller, S. Laffer, C. Harwanegg, M. Huber, W. Schmidt et al., Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment, The FASEB Journal
DOI : 10.1096/fj.01-0711fje

C. Sturgeon, B. Hoffman, D. Chan, S. Ch-'ng, E. Hammond et al., National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements, Clinical Chemistry, vol.54, issue.8, pp.1-10, 2008.
DOI : 10.1373/clinchem.2007.094144

A. Ellington, I. Kullo, K. Bailey, and G. Klee, Measurement and Quality Control Issues in Multiplex Protein Assays: A Case Study, Clinical Chemistry, vol.55, issue.6, pp.1092-1101, 2009.
DOI : 10.1373/clinchem.2008.120717

L. Kricka and S. Master, Quality Control and Protein Microarrays, Clinical Chemistry, vol.55, issue.6, 2009.
DOI : 10.1373/clinchem.2009.126557

D. Hamelinck, H. Zhou, L. Li, C. Verweij, D. Dillon et al., Optimized Normalization for Antibody Microarrays and Application to Serum-Protein Profiling, Molecular & Cellular Proteomics, vol.4, issue.6, pp.773-84, 2005.
DOI : 10.1074/mcp.M400180-MCP200

L. Shi, Executive summary: the MicroArray Quality Control (MAQC) project: toward consensus on Best Practices " for the generation, analysis, and application of microarray data in the discovery, development, and review of FDA-regulated products, 2006.

M. Chen, P. Lin, C. Wu, W. Chen, and C. Wu, IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer, PLoS One, 2013.

V. Urquidi, M. Chang, Y. Dai, J. Kim, E. Wolfson et al., IL-8 as a urinary biomarker for the detection of bladder cancer, BMC Urology, vol.13, issue.1, p.12, 2012.
DOI : 10.1016/S0022-5347(05)65290-1

Y. Luo, E. Askeland, M. Newton, O. Donnell, and M. , Role of IL-10 in Urinary Bladder Carcinoma and Bacillus Calmette-Guerin Immunotherapy, Am J Immunol, vol.8, issue.1, pp.1-9, 2012.

B. Corgier, C. Mandon, L. Goff, G. Blum, L. Marquette et al., Adhesive microarrays for multipurpose diagnostic tools. Lab Chip, pp.3006-3016, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00631239

P. Buchegger, U. Sauer, H. Toth-szekely, and C. Preininger, Miniaturized Protein Microarray with Internal Calibration as Point-of-Care Device for Diagnosis of Neonatal Sepsis. Sensors, Feb, vol.312, issue.2, pp.1494-508, 2012.

C. Fredolini, F. Meani, K. Reeder, S. Rucker, A. Patanarut et al., Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles, Nano Research, vol.62, issue.Suppl1, pp.502-520, 2008.
DOI : 10.1007/s12274-008-8054-z

S. Lehmann, S. Roche, Y. Allory, A. Barthelaix, J. Beaudeux et al., Preanalytical guidelines for clinical proteomics investigation of biological fluids, Ann Biol Clin, vol.67, issue.6, pp.629-668, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00444355